Bayer Opens Pharma Plant In Pakistan
German chemicals and drugs major Bayer AG has brought on stream a newpharmaceutical manufacturing plant in Karachi, Pakistan, aiming to strengthen its local capacity for tablet and cream-based treatments. The new production facility was built at a total cost of 230 million rupees (around $6 million). Bayer has been manufacturing in Pakistan for more than 30 years.
The line of products to be made at the new Karachi site include Bayer's antibiotic Ciprobay (ciprofloxacin), which is sold in Pakistan under the Ciproxin name, the malaria treatment Resochin, the antidiabetes drug Glucobay (acarbose) and the antihypertensive Adalat (nifedipine). Also to be produced at the site is the firm's broad-spectrum antifungal Canesten (clotrimazole), which Bayer says is the leading mycotic on the local market.
Speaking at the inauguration, Clemens Kaiser, head of Bayer's pharmaceutical operations in Asia, Africa, South America and eastern Europe, said the company has "great confidence" in Pakistan's business environment, especially health care.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze